Skip to content
PsychedeliaDokholyan Laboratory
Plate 530 of 545Verified

Tryptamine

Also known as2-(1H-Indol-3-yl)ethanamine · 3-(2-aminoethyl)indole · 1H-Indole-3-ethanamine · 2-(3-Indolyl)ethylamine · 2-(1H-Indol-3-Yl)Ethan-1-Amine · beta-(3-Indolyl)ethylamine · 3-[2-Aminoethyl]indole · Indol-3-ethylamine

2-(1H-indol-3-yl)ethanamine

PubChem CID
1150
Measurements
88
InChIKey
APJYDQYYACXCRM-UHFFFAOYSA-N

I · Summary

What is known

Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.

What it is

  • Tryptamine is an aminoalkylindole consisting of indole having a 2-aminoethyl group at the 3-position. It has a role as a mouse metabolite, a plant metabolite and a human metabolite. It is a member of tryptamines, an aminoalkylindole, an indole alkaloid and an aralkylamino compound. It is a conjugate base of a tryptaminium.

    ChEBI

  • tryptamine has been reported in Polygala tenuifolia, Rauvolfia serpentina, and other organisms with data available.

    LOTUS - the natural products occurrence database

History, discovery and cultural use

— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Tryptamine was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.

Histories of this field

Scholarship on psychedelics generally, not on Tryptamine specifically. Whether any of these treats this compound is a question for the book, not for this page.

  • Mescaline: A Global History of the First Psychedelic

    Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.

    Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.

  • Expanding Mindscapes: A Global History of Psychedelicsopen access

    Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.

    Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.

  • Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers

    Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.

    Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.

  • Psychonauts: Drugs and the Making of the Modern Mind

    The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.

    Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.

  • Ancient Psychoactive Substances

    Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.

    Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.

  • History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders

    A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.

    Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.

    Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.

  • Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

    Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.

    Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.

Institutional archives

  • Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
  • Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.

The rest of this dossier

  • Affinity — 88 measurements in this archive, equilibrium constants kept apart from functional readouts.
  • Toxicology — nothing published for Tryptamine. An absent record is an absence of study, not evidence of safety.
  • Legal — no DEA record is held here — which is not a finding that this compound is uncontrolled.
  • Systems — where this compound’s targets are transcribed, by brain region and tissue.

Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Tryptamine is the history note, which says so on its face and carries a reference for every claim in it.

II · Identity

Structure and descriptors

Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.

2D structural depiction of Tryptamine
Depiction served by PubChem for CID 1150. Not redrawn here, so the picture and the identity come from the same record.
Formula
C10H12N2R
Molecular weight
160.22g/molR
Exact mass
160.1000DaR
cLogP
1.67R
TPSA
41.8ŲR
H-bond donors
2R
H-bond acceptors
1R
Rotatable bonds
2R
Aromatic rings
2R
Heavy atoms
12R
Fraction sp³
0.200R
Formal charge
0R

Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.

Bemis–Murcko scaffold

c1ccc2[nH]ccc2c1

Shared with 1-Acetyl-5-MeO-DMT, 1-Methylpsilocin, 2-Me-DET, 2-Methyltryptamine, 2,N,N-TMT, 4-AcO-DALT and 81 more. All families

III · Behavior

Behavioral summary

Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.

Classification

MeSH indexes no pharmacological class for this compound.

Duration of acute subjective effects

—

No controlled human trial reporting a duration for this compound is cited here. The archive holds no other record of one either. A duration is not inferred from a chemical relative.

Plasma elimination half-life

How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.

No half-life is published for this compound in the sources this site reads.

Primary pharmacological drivers

ChEMBL holds no curated mechanism-of-action record for this compound. The measured affinities below are the evidence this archive has for what it binds.

Nothing about this compound’s pharmacology is published with a citation in the sources this site reads. The measured binding data below is what the archive can show.

IV · Clinical

Clinical description

Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.

No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.

How much has been written about each domain

The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.

None of the 0 records this archive holds for this compound uses a term from any of the clinical domains. That is a statement about the literature recorded here, not about the compound.

V · Systems

Systems physiology

Where the targets this compound binds are transcribed — brain regions on the left, peripheral and autonomic tissues on the right. A join of two measurements, not a claim about what the compound does to either.

Brain

cerebral cortex — 18.2 nTPM, from HTR2A, HTR1A, DRD1cerebellum — 1.0 nTPM, from HTR1E, HTR2A, DRD1hippocampal formation — 6.1 nTPM, from HTR1A, HTR2A, HTR2Camygdala — 3.5 nTPM, from HTR2A, HTR2C, HTR1Ahypothalamus — 12.6 nTPM, from HTR2C, HTR2A, HTR7thalamus — no resolved target expressed herebasal ganglia — 28.2 nTPM, from HTR2C, DRD1, HTR6medulla oblongata — no resolved target expressed here

basal ganglia: drawn as the caudate nucleus, putamen and globus pallidus.

Measured but not drawn — this anatomogram has no outline for them: retina 7.8, midbrain 2.2, spinal cord 1.0, pituitary gland 0.4.

Body

heart — 4.6 nTPM, from HTR2B, HTR2A, HTR7smooth muscle — 15.7 nTPM, from HTR2B, HTR2A, HTR1Elung — 0.8 nTPM, from HTR2B, DRD1, HTR2Aliver — 1507.9 nTPM, from CYP2A6, HTR2B, CYP2A13kidney — 3.1 nTPM, from HTR2B, DRD1, HTR1Bstomach — 4.7 nTPM, from HTR1B, HTR2B, HTR1Eduodenum — 8.0 nTPM, from HTR1D, HTR2B, HTR7small intestine — 7.1 nTPM, from HTR1D, HTR2B, HTR7colon — 8.5 nTPM, from HTR2B, HTR7, HTR2Aadrenal gland — 17.2 nTPM, from HTR2B, HTR1B, DRD1thyroid gland — 3.2 nTPM, from HTR2B, HTR1E, HTR1Fpancreas — 0.2 nTPM, from HTR2B, HTR1D, HTR1Furinary bladder — 2.1 nTPM, from HTR7, HTR2B, HTR1Bskeletal muscle — 0.9 nTPM, from HTR7, HTR2A, HTR2Bspleen — 1.0 nTPM, from HTR7, HTR1F, HTR2Bsalivary gland — 0.4 nTPM, from HTR2B, HTR7, HTR1B
01508 nTPM

Square-root ramp · shared scale across both plates

Shading is transcript level — not affinity, and not affinity combined with expression. Outlined but unshaded organs hold none of this compound’s resolved targets above the atlas’s detection threshold. Anatomy from EMBL-EBI Anatomogram (Apache License 2.0); regions identified by Uberon (uberon.org), CC BY 3.0.

Brain regions

Regions where this compound's measured targets are transcribed. Linked from the plate above.

  1. basal ganglia

    28.2 nTPM

  2. cerebral cortex

    18.2 nTPM

  3. hypothalamus

    12.6 nTPM

  4. retina

    7.8 nTPM

  5. hippocampal formation

    6.1 nTPM

  6. amygdala

    3.5 nTPM

  7. midbrain

    2.2 nTPM

  8. spinal cord

    1.0 nTPM

  9. cerebellum

    1.0 nTPM

  10. pituitary gland

    0.4 nTPM

Peripheral & autonomic

Tissues outside the CNS expressing the same targets — where a compound's bodily effects become possible.

  1. liver

    1507.9 nTPM
    • Cytochrome P450 2A6CYP2A65.8 pX1507.9
    • 5-HT2BHTR2B7.6 pX3.3
    • Cytochrome P450 2A13CYP2A135.3 pX1.9
    • D1DRD16.0 pX1.0
    • 5-HT7HTR77.8 pX0.4
    • and 1 more

  2. adrenal gland

    17.2 nTPM

  3. smooth muscle

    15.7 nTPM

  4. colon

    8.5 nTPM

  5. duodenum

    8.0 nTPM

  6. small intestine

    7.1 nTPM

  7. stomach 1

    4.7 nTPM

  8. heart muscle

    4.6 nTPM

  9. thyroid gland

    3.2 nTPM

  10. kidney

    3.1 nTPM

  11. urinary bladder

    2.1 nTPM

  12. spleen

    1.0 nTPM

  13. skeletal muscle

    0.9 nTPM

  14. lung

    0.8 nTPM

  15. salivary gland

    0.4 nTPM

  16. pancreas

    0.2 nTPM

Each row joins two published measurements and nothing else: the affinity this archive holds for the compound at that target, and the transcript level the Human Protein Atlas reports for that target’s gene in that region. Bars scale with expression only. Expression is not activation — a receptor transcribed in a region is a receptor available to be bound there, which is a weaker and more defensible claim than saying the region is affected.

3 of this compound’s targets could not be resolved to a gene and are absent from both columns: 5-HT2, Adrenergic receptor alpha-2, Myeloperoxidase.

Expression data from Human Protein Atlas (CC BY-SA 3.0), RNA expression, nTPM (normalized transcripts per million), consensus tissue dataset. Uhlén M, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

VI · Profile

Affinity rosette

The strongest measurement at each of 16 molecular targets. Cell-line and whole-organism screens are excluded here — they carry no affinity — and appear in the table below.

5-HT2A — Ki 7.96 pX5-HT7 — Ki 7.79 pX5-HT2B — Ki 7.60 pX5-HT1B — Ki 7.44 pX5-HT1D — Ki 7.44 pX5-HT2C — Ki 7.34 pX5-HT2 — Ki 7.30 pX5-HT6 — Ki 7.15 pX5-HT1A — Ki 6.98 pX5-HT1F — Ki 5.62 pX5-HT1E — Ki 5.59 pXD1 — Ki 5.96 pXAdrenergic receptor alpha-2 — Ki 4.72 pXMyeloperoxidase — IC50 6.11 pXCytochrome P450 2A6 — Ki 5.77 pXCytochrome P450 2A13 — Kd 5.28 pX5-HT2A5-HT75-HT2B5-HT1B5-HT1D5-HT2C5-HT25-HT65-HT1A5-HT1F5-HT1ED1Adrenergic recep…MyeloperoxidaseCytochrome P450 …Cytochrome P450 …579
Fig. Radius is pX = −log₁₀(value in M), that is 9 − log₁₀(value in nM), computed from the normalized measurement. Hatched wedges are equilibrium binding constants (Ki, Kd); dashed outlines are functional readouts (IC₅₀, EC₅₀, AC₅₀, potency), which answer a different question and are not pooled with them. Rings mark whole pX units from 5 to 10, labeled every second ring in the gutter at the top. Where a target carries several measurements, the strongest is drawn.

VII · Toxicology

Toxicological profile

What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.

Measured in this archive

Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.

Cytochrome P450 inhibition 4

Inhibition of a drug-metabolising enzyme, which is how interactions arise — the harmala alkaloids' MAO inhibition is the same kind of fact, and appears with the measurements above.

Published toxicology

— None. The toxicology databases this site reads — HSDB, RTECS and LiverTox, by way of PubChem — hold no record for Tryptamine. They index compounds that have been studied for decades, so most of this archive has no entry. An absent record is an absence of study, not evidence of safety.

Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.

VIII · Evidence

Every measurement

One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.

Equilibrium binding constants 86

Ki and Kd — a concentration at equilibrium. Directly comparable across rows at the same target.

TargetClassTypeValue (nM)pXOrganismAssay
5-HT2ASerotonin receptorsKi11.007.96RATPMID 2795135
5-HT7Serotonin receptorsKi16.217.79RATPMID 7984267
5-HT7Serotonin receptorsKi16.407.79RATPMID 8394362
5-HT7Serotonin receptorsKi19.057.72GUINEA PIGPMID 7647964
5-HT2ASerotonin receptorsKi25.117.60RATPMID 7984267
5-HT2BSerotonin receptorsKi25.117.60HUMANPMID 9225287
5-HT2BSerotonin receptorsKi29.517.53HUMANPMID 10498829
5-HT7Serotonin receptorsKi32.807.48RATPMID 8394362
5-HT7Serotonin receptorsKi33.117.48RATPMID 7984267
5-HT1BSerotonin receptorsKi36.007.44Homo sapiensCHEMBL617320
5-HT1DSerotonin receptorsKi36.007.44BOVINEPDSP
5-HT1DSerotonin receptorsKi39.807.40CALFPDSP
5-HT1DSerotonin receptorsKi40.007.40BOVINEPMID 1565658
5-HT1DSerotonin receptorsKi41.707.38HUMANPDSP
5-HT2CSerotonin receptorsKi45.717.34HUMANPMID 10498829
5-HT1DSerotonin receptorsKi46.007.34HUMANPDSP
5-HT2CSerotonin receptorsKi46.807.33PIGPDSP
5-HT2CSerotonin receptorsKi46.807.33PIGPDSP
5-HT2Serotonin receptorsKi50.007.30Rattus norvegicusCHEMBL617413
5-HT2CSerotonin receptorsKi50.007.30Homo sapiensCHEMBL616819
5-HT2CSerotonin receptorsKi50.107.30PIGPDSP
5-HT2CSerotonin receptorsKi56.237.25RATPMID 9225287
5-HT1DSerotonin receptorsKi61.007.21Homo sapiensCHEMBL617599
5-HT2CSerotonin receptorsKi62.007.21RATPMID 10611640
5-HT2CSerotonin receptorsKi62.007.21RATPMID 9928251
5-HT7Serotonin receptorsKi64.567.19GUINEA PIGPMID 7647964
5-HT6Serotonin receptorsKi70.007.15Homo sapiensCHEMBL3062227
5-HT2BSerotonin receptorsKi73.207.14HUMANPMID 8632342
5-HT2CSerotonin receptorsKi79.437.10PORCINEPMID 10611634
5-HT1DSerotonin receptorsKi85.107.07CALFPDSP
5-HT1DSerotonin receptorsKi85.107.07COWPDSP
5-HT1DSerotonin receptorsKi85.117.07HUMANPMID 7984267
5-HT1BSerotonin receptorsKi86.007.07HUMANPMID 1565658
5-HT2ASerotonin receptorsKi89.127.05HUMANPMID 7984267
5-HT2BSerotonin receptorsKi1026.99HUMANPMID 15322733
5-HT1ASerotonin receptorsKi1056.98HUMANPMID 7984267
5-HT2BSerotonin receptorsKi1126.95RATPMID 7984267
5-HT2BSerotonin receptorsKi1136.95RATPMID 8632342
5-HT7Serotonin receptorsKi1486.83HUMANPMID 7984267
5-HT7Serotonin receptorsKi1496.83HUMANPMID 8226867
5-HT6Serotonin receptorsKi1586.80RATPMID 9225298
5-HT1ASerotonin receptorsKi1706.77Rattus norvegicusCHEMBL616344
5-HT1ASerotonin receptorsKi1706.77Rattus norvegicusCHEMBL615963
5-HT2BSerotonin receptorsKi2006.70MOUSEPMID 7984267
5-HT2BSerotonin receptorsKi2006.70RATPMID 7984267
5-HT2ASerotonin receptorsKi2196.66HUMANPMID 15322733
5-HT1DSerotonin receptorsKi2246.65PIGPDSP
5-HT2ASerotonin receptorsKi2576.59HUMANPMID 10498829
5-HT1DSerotonin receptorsKi2956.53CALFPDSP
5-HT2CSerotonin receptorsKi2956.53HUMANPMID 9225287
5-HT1DSerotonin receptorsKi3476.46DogPMID 7984267
5-HT2ASerotonin receptorsKi4176.38RATPMID 9225287
5-HT6Serotonin receptorsKi4386.36HUMANPMID 8226867
5-HT6Serotonin receptorsKi4386.36RATPMID 7680751
5-HT1DSerotonin receptorsKi5216.28HUMANPMID 1565658
5-HT1BSerotonin receptorsKi5256.28HUMANPMID 7984267
5-HT2BSerotonin receptorsKd5376.27Rattus norvegicusCHEMBL617633
5-HT2ASerotonin receptorsKi5896.23HUMANPMID 9225287
5-HT2CSerotonin receptorsKi7726.11RATPMID 10611640
5-HT2CSerotonin receptorsKi7726.11RATPMID 9928251
5-HT2ASerotonin receptorsKi1,0006.00RATPDSP
5-HT1BSerotonin receptorsKi1,0205.99RATPDSP
D1Dopamine receptorsKi1,0845.96HUMANPMID 11459929
5-HT2ASerotonin receptorsKi1,1205.95RATPDSP
5-HT2ASerotonin receptorsKi1,1215.95RATPDSP
5-HT2BSerotonin receptorsKi1,3005.89BOVINEPMID 2795135
5-HT6Serotonin receptorsKi1,4795.83RATPMID 9225298
Cytochrome P450 2A6EnzymesKi1,7005.77Homo sapiensCHEMBL3532209
5-HT2ASerotonin receptorsKi2,0055.70RATPDSP
5-HT2ASerotonin receptorsKi2,2455.65HUMANPDSP
Cytochrome P450 2A6EnzymesKd2,3005.64Homo sapiensCHEMBL3532204
5-HT2CSerotonin receptorsKi2,3445.63HUMANPMID 15322733
5-HT1FSerotonin receptorsKi2,4095.62HUMANPMID 8380639
5-HT1ESerotonin receptorsKi2,5595.59HUMANPMID 1513320
5-HT2ASerotonin receptorsKi2,8865.54RATPDSP
5-HT2ASerotonin receptorsKi2,8945.54RATPDSP
5-HT2Serotonin receptorsKi2,8955.54Rattus norvegicusCHEMBL617444
5-HT2ASerotonin receptorsKi3,1595.50RATPDSP
5-HT2ASerotonin receptorsKi3,1625.50HUMANPMID 7984267
5-HT1ASerotonin receptorsKi3,7155.43RATPMID 6225026
5-HT2ASerotonin receptorsKi3,8905.41RATPMID 7984267
Cytochrome P450 2A13EnzymesKd5,2005.28Homo sapiensCHEMBL3535230
UncheckedUnclassifiedKi5,4005.27— organism not recordedCHEMBL881456
5-HT1BSerotonin receptorsKi10,2004.99Rattus norvegicusCHEMBL616773
Cytochrome P450 2A13EnzymesKi16,0004.80Homo sapiensCHEMBL3532208
Adrenergic receptor alpha-2Adrenergic receptorsKi19,0004.72Rattus norvegicusCHEMBL648713

Functional readouts 2

IC₅₀, EC₅₀, AC₅₀ and potency. Assay-dependent, and not interchangeable with a binding constant.

TargetClassTypeValue (nM)pXOrganismAssay
MyeloperoxidaseEnzymesIC507706.11Homo sapiensCHEMBL2352940
Cathepsin KUnclassifiedIC5015,0004.82Homo sapiensCHEMBL938815
P
PubChem
C
ChEMBL
R
Computed here with RDKit
D
Derived here from the stored measurement

IX · Trials

Registered clinical trials

Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.

1T

Registered studies

0T

Open or ongoing

1T

With a phase recorded

The registry returned more studies than this fetch retrieved, so the counts above are a floor rather than a total. Follow the registry link below for the full set.

By phase

A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.

  • Phase 31

By status

The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.

  • Terminated1

Every matched study

Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.

  • NCT00227136Terminated · Phase 3

    Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion

    Enrollment
    8Tnot qualified
    Started
    2005-05
    Sponsor
    University of Western Ontario, Canada

    Conditions Carcinoid Tumors · Neuroendocrine Tumors

    Matched “Tryptamine” in the study’s intervention “5-Hydroxy-Tryptamine”

Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.

Searched as Tryptamine · 2-(1H-Indol-3-yl)ethanamine · 3-(2-aminoethyl)indole. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.

A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Tryptamine worked.

XI · Literature

Sources behind this dossier

The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.

Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.

  1. 01

    Molecular biology of 5-HT receptors

    Boess FG, Martin IL · Neuropharmacology 1994

    • · 14 measurements at 6 targets (Ki), strongest 5-HT7 at 7.79 pX

    PMID 7984267

  2. 02

    RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist

    Bonhaus DW, Weinhardt KK, Taylor M et al. · Neuropharmacology 1997

    • · 5 measurements at 3 targets (Ki), strongest 5-HT2B at 7.60 pX

    PMID 9225287

  3. 03

    Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors

    Knight AR, Misra A, Quirk K et al. · Naunyn-Schmiedeberg's archives of pharmacology 2004

    • · 3 measurements at 3 targets (Ki), strongest 5-HT2B at 6.99 pX

    PMID 15322733

  4. 04

    Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells

    Porter RH, Benwell KR, Lamb H et al. · British journal of pharmacology 1999

    • · 3 measurements at 3 targets (Ki), strongest 5-HT2B at 7.53 pX

    PMID 10498829

  5. 05

    Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta

    Weinshank RL, Zgombick JM, Macchi MJ et al. · Proceedings of the National Academy of Sciences of the United States of America 1992

    • · 3 measurements at 2 targets (Ki), strongest 5-HT1D at 7.40 pX

    PMID 1565658

  6. 06

    Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors

    Egan C, Grinde E, Dupre A et al. · Synapse (New York, N.Y.) 2000

    • · 2 measurements at 1 target (Ki), strongest 5-HT2C at 7.21 pX

    PMID 10611640

  7. 07

    Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor

    Herrick-Davis K, Grinde E, Gauthier C et al. · Annals of the New York Academy of Sciences 1998

    • · 2 measurements at 1 target (Ki), strongest 5-HT2C at 7.21 pX

    PMID 9928251

  8. 08

    Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells

    Boess FG, Monsma FJ Jr, Carolo C et al. · Neuropharmacology 1997

    • · 2 measurements at 1 target (Ki), strongest 5-HT6 at 6.80 pX

    PMID 9225298

  9. 09

    Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences

    Wainscott DB, Lucaites VL, Kursar JD et al. · The Journal of pharmacology and experimental therapeutics 1996

    • · 2 measurements at 1 target (Ki), strongest 5-HT2B at 7.14 pX

    PMID 8632342

  10. 10

    Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain

    To ZP, Bonhaus DW, Eglen RM et al. · British journal of pharmacology 1995

    • · 2 measurements at 1 target (Ki), strongest 5-HT7 at 7.72 pX

    PMID 7647964

  11. 11

    Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase

    Bard JA, Zgombick J, Adham N et al. · The Journal of biological chemistry 1993

    • · 2 measurements at 2 targets (Ki), strongest 5-HT7 at 6.83 pX

    PMID 8226867

  12. 12

    Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype

    Shen Y, Monsma FJ Jr, Metcalf MA et al. · The Journal of biological chemistry 1993

    • · 2 measurements at 1 target (Ki), strongest 5-HT7 at 7.79 pX

    PMID 8394362

  13. 13

    Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin

    McKenna DJ, Peroutka SJ · The Journal of neuroscience : the official journal of the Society for Neuroscience 1989

    • · 2 measurements at 2 targets (Ki), strongest 5-HT2A at 7.96 pX

    PMID 2795135

  14. 14

    Trace amines: identification of a family of mammalian G protein-coupled receptors

    Borowsky B, Adham N, Jones KA et al. · Proceedings of the National Academy of Sciences of the United States of America 2001

    • · 1 measurement at 1 target (Ki), strongest D1 at 5.96 pX

    PMID 11459929

  15. 15

    Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

    Millan MJ, Newman-Tancredi A, Audinot V et al. · Synapse (New York, N.Y.) 2000

    • · 1 measurement at 1 target (Ki), strongest 5-HT2C at 7.10 pX

    PMID 10611634

  16. 16

    Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs

    Monsma FJ Jr, Shen Y, Ward RP et al. · Molecular pharmacology 1993

    • · 1 measurement at 1 target (Ki), strongest 5-HT6 at 6.36 pX

    PMID 7680751

  17. 17

    Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase

    Adham N, Kao HT, Schecter LE et al. · Proceedings of the National Academy of Sciences of the United States of America 1993

    • · 1 measurement at 1 target (Ki), strongest 5-HT1F at 5.62 pX

    PMID 8380639

  18. 18

    Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor

    Zgombick JM, Schechter LE, Macchi M et al. · Molecular pharmacology 1992

    • · 1 measurement at 1 target (Ki), strongest 5-HT1E at 5.59 pX

    PMID 1513320

  19. 19

    Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT

    Gozlan H, El Mestikawy S, Pichat L et al. · Nature 1983

    • · 1 measurement at 1 target (Ki), strongest 5-HT1A at 5.43 pX

    PMID 6225026